Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path

Luxuan Guo1,2,3, Yue Ji4, Tianhao Sun1,2,3

  • 1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 300193 Tianjin, China.

Insights

Heart failure (HF) management in dialysis patients requires tailored approaches due to unique health challenges. This review offers new perspectives on diagnosing and treating HF in this population.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Chronic heart failure (CHF) is a leading cause of mortality in dialysis patients.
  • Existing heart failure (HF) guidelines are often inadequate for dialysis populations due to renal dysfunction and treatment specifics.
  • There is a critical need for evidence-based strategies for managing HF in patients undergoing dialysis.

Purpose of the Study:

  • To review and synthesize current knowledge on HF management in dialysis patients.
  • To highlight the differences in HF diagnosis and treatment between the general population and dialysis patients.
  • To provide updated perspectives and future directions for clinical practice.

Main Methods:

  • Comprehensive literature review of existing guidelines and clinical studies.
  • Focus on staging, diagnosis, risk factor management, pharmacotherapy, and dialysis-specific treatments for HF.
  • Analysis of evidence-based medicine and clinical trial data.

Main Results:

  • Dialysis patients present unique challenges in HF management compared to the general population.
  • Current guidelines require adaptation to address the specificities of hemodialysis (HD) and peritoneal dialysis (PD).
  • The review synthesizes new insights into HF diagnosis and treatment for this cohort.

Conclusions:

  • Standard HF guidelines need modification for dialysis patients.
  • A tailored, evidence-based approach is crucial for optimizing HF care in dialysis populations.
  • This review aims to standardize and improve clinical understanding and management of HF in patients on dialysis.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
286
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555